64 results on '"Edwards, I. Ralph"'
Search Results
2. Challenges of safe medication practice in paediatric care – a nursing perspective
3. Communicating the New Pharmacovigilance Landscape
4. Decision Dilemmas: Worse in Emerging Economies
5. Good Pharmacovigilance Practice and the Curateʼs Egg
6. Good Pharmacovigilance Practice and the Curateʼs Egg
7. Clinical Diagnosis: A Topic Worth Revisiting for Pharmacovigilance
8. Prevention and Pharmacovigilance: What Should We Do, What Can We Do?
9. Patient Follow-Up and Monitoring Medicines
10. Communication in Drug Safety: A Report from an Interactive Debate Held at the 10th Annual Meeting of the International Society of Pharmacovigilance (ISoP), 2010
11. Off-Label Pharmacovigilance
12. The Authorʼs Reply
13. Conflicts of Interest in Medicines Safety and Regulation: How Much Conflict and How Much Interest Should We Allow?
14. Fraudulent and Substandard Medicines: Getting Away with Murder?
15. Suspected Adverse Drug Reactions Reported For Children Worldwide: An Exploratory Study Using VigiBase
16. Social Media and Networks in Pharmacovigilance: Boon or Bane?
17. Dose Variations Associated with Formulations of NSAID Prescriptions for Children: A Descriptive Analysis of Electronic Health Records in the UK
18. Reporting Patterns Indicative of Adverse Drug Interactions: A Systematic Evaluation in VigiBase
19. Pharmacovigilance and the Null Hypothesis: Do We do Much for Public Health?
20. African Heat
21. Reflections on Attribution and Decisions in Pharmacovigilance
22. What do Stakeholders Think about Pharmacovigilance?
23. Placebo Harm
24. First, Catch Your Signal!
25. Wonder Vigilance
26. Tomorrowʼs World
27. A Risk Worth Taking?
28. Modern methods of pharmacovigilance: detecting adverse effects of drugs
29. Outliers and Patients with Adverse Drug Reactions
30. Understanding and Communicating Key Concepts in Risk Management: What do we Mean by Benefit and Risk?
31. The Good Old Drugs!
32. The ISoP Bengt-Erik Wiholm Memorial Lecture
33. Risk Management of Medicines and Compensation for Harm
34. Stratification for Spontaneous Report Databases
35. Stratification for Spontaneous Report Databases
36. Controlled Trials and Risk of Harm
37. Impact of Stratification on Adverse Drug Reaction Surveillance
38. TNF-α Inhibitors and Leukaemia: International Pharmacovigilance Reports
39. The Author’s Reply
40. Drug–drug interactions – a preventable patient safety issue?
41. Statins, Neuromuscular Degenerative Disease and an Amyotrophic Lateral Sclerosis-Like Syndrome: An Analysis of Individual Case Safety Reports from Vigibase
42. What is Drug Safety?: Celebrating 20 Years of the Drug Safety Journal
43. What are the Real Lessons from Vioxx®?
44. The WHO World Alliance for Patient Safety: A New Challenge or an Old One Neglected?
45. Assessing the Impact of Drug Safety Signals from the WHO Database Presented in ‘SIGNAL’: Results from a Questionnaire of National Pharmacovigilance Centres
46. Labelling and ‘Dear Doctor’ Letters: Are They Noncommittal?
47. Signal Selection and Follow-Up in Pharmacovigilance
48. A Data Mining Approach for Signal Detection and Analysis
49. Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study
50. Adverse drug reactions: definitions, diagnosis, and management
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.